SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028. Shares were recently up 8.3% ...
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett ...
Hosted on MSN
Neuren Pharmaceuticals’ partner Acadia gains FDA approval for new Rett syndrome treatment
Neuren Pharmaceuticals Limited ( (AU:NEU)) has provided an update. Neuren Pharmaceuticals announced that its partner, Acadia Pharmaceuticals, has received FDA approval for DAYBUE STIX, a new powder ...
Netball New Zealand chief executive Jennie Wyllie has resigned from her role. Wyllie’s resignation was communicated to staff this morning. She is understood to have told staff she plans to spend time ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback